Program
Lu AF28996
A development code. Also written as “Lu AF28996 solution” and “Lu AF28996 capsule”.
Its studies are mostly in Parkinson Disease, led by H. Lundbeck.
Furthest: phase 2, since Mar 31, 20266 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| H. Lundbeck | 62 open or running | phase 2since Mar 31, 2026 | Jun 8, 2018 | May 31, 2027phase 1 · NCT07513441 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 8, 2018First study: phase 1 study in HealthyFirst studyNCT03565094 · 39 enrolled · Netherlands
- Feb 28, 2020Phase 1 study in Parkinson DiseaseNCT04291859 · 57 enrolled · United States, France, Germany and more
- Aug 16, 2023Phase 1 study in Parkinson DiseaseNCT06004180 · 6 enrolled · Japan
- Mar 22, 2024Phase 1 study in Healthy ParticipantsNCT06337110 · 8 enrolled · United Kingdom
- Mar 31, 2026Phase 2 study in Parkinson DiseasePhase 2 reachedNCT07514858 · 150 planned · United States, Czechia, Germany and more
- Mar 31, 2026Phase 1 study in Parkinson DiseaseNCT07513441 · 10 planned · China
Ahead
- May 31, 2027Primary completion: phase 1 study in Parkinson DiseaseNCT07513441
- Oct 3, 2028Primary completion: phase 2 study in Parkinson DiseaseNCT07514858
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07514858Parkinson Disease · United States, Czechia, Germany and more | 2 | Recruiting | Oct 3, 2028 | 150 |
| NCT07513441Parkinson Disease · China | 1 | Recruiting | May 31, 2027 | 10 |
| NCT06337110Healthy Participants · United Kingdom | 1 | Completed | May 11, 2024 | 8 |
| NCT06004180Parkinson Disease · Japan | 1 | Completed | Nov 21, 2023 | 6 |
| NCT04291859Parkinson Disease · United States, France, Germany and more | 1 | Completed | Oct 14, 2025 | 57 |
| NCT03565094Healthy · Netherlands | 1 | Completed | Aug 17, 2019 | 39 |
How it is read
Names in the registry
- “Lu AF28996”, 5 entries
- “Lu AF28996 solution”, 1 entry
- “Lu AF28996 capsule”, 1 entry
Codes read as this program: LUAF28996.
Conditions, from the studies’ own filings
- Parkinson Disease, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.